Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
26.68
+0.34 (1.29%)
At close: Jun 26, 2026, 4:00 PM EDT
26.75
+0.07 (0.26%)
After-hours: Jun 26, 2026, 7:57 PM EDT
Company Description
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States.
It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020.
Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Mineralys Therapeutics, Inc.
| Country | United States |
| Founded | 2019 |
| IPO Date | Feb 10, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 76 |
| CEO | Jon Congleton |
Contact Details
Address: 150 N. Radnor Chester Road, Suite F200 Radnor, Pennsylvania 19087 United States | |
| Phone | 888 378 6240 |
| Website | mineralystx.com |
Stock Details
| Ticker Symbol | MLYS |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001933414 |
| CUSIP Number | 603170101 |
| ISIN Number | US6031701013 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jon Congleton | President, Chief Executive Officer and Director |
| Dr. Brian Taylor Slingsby M.D., M.P.H., Ph.D. | Founder and Executive Director |
| Adam Scott Levy | Chief Financial Officer and Secretary |
| Dr. David M. Rodman M.D. | Chief Medical Officer |
| Jeffrey A. Munsie J.D. | Chief Legal Officer |
| Dr. Robert McKean Ph.D. | Senior Vice President of CMC |
| Danielle Mahoney | Senior Vice President of Quality Assurance |
| Jessica Ibbitson | Executive Vice President of Operations |
| Eric J. Warren R.Ph. | Chief Commercial Officer |
| Tiffany Ellen Burt | Senior Vice President of Medical Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 17, 2026 | 144 | Filing |
| Jun 17, 2026 | 144 | Filing |
| Jun 15, 2026 | 144 | Filing |
| Jun 12, 2026 | 144 | Filing |
| Jun 10, 2026 | 144 | Filing |
| Jun 3, 2026 | 8-K | Current Report |
| Jun 3, 2026 | 424B5 | Filing |
| Jun 3, 2026 | 8-K | Current Report |
| May 22, 2026 | 8-K | Current Report |
| May 18, 2026 | 144 | Filing |